Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180820 | 0.84 | TGFBR1 (0.48) | ROCK2ROCK1TGFBR1ALDH1A1LMNA | |
| SCHEMBL6179158 | 0.81 | TGFBR1 (0.53) | ROCK2TGFBR1 | |
| SCHEMBL6178605 | 0.78 | TGFBR1 (0.70) | TGFBR1DRD2 | |
| SCHEMBL12444984 | 0.78 | TGFBR1 (0.57) | ROCK2ROCK1TGFBR1KDM4EALDH1A1 | |
| SCHEMBL24312340 | 0.77 | TGFBR1 (0.56) | TGFBR1IKBKBKDM4E | |
| SCHEMBL6180797 | 0.75 | TGFBR1 (0.42) | TGFBR1 | |
| SCHEMBL373292 | 0.75 | TGFBR1 (0.66) | TGFBR1KDM4EALDH1A1MAPT | |
| SCHEMBL29358505 | 0.75 | TGFBR1 (0.70) | TGFBR1 | |
| SCHEMBL373524 | 0.75 | TGFBR1 (0.70) | TGFBR1 | |
| Water SCHEMBL21633982 | 0.74 | TGFBR1 (0.69) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | claimed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | claimed |
| EP-1355903-B1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | SMITHKLINE BEECHAM CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | ROCK2 1102/4885ROCK1 458/4885MCHR1 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.